Gabrielle Lyon: HRT and Breast Cancer – Separating Myth from Medical Evidence | Dr. Heather Hirsch
Peer-Reviewed Research
Key Takeaways
- Hormone replacement therapy (HRT) benefits outweigh risks when started near menopause (ages 46-55): reduces heart disease (leading cause of death in women) and improves bone health.
- Bioidentical progesterone (not synthetic progestins) shows no increased breast cancer risk when paired with estrogen.
- The 26% increased breast cancer risk from the 2002 WHI study translates to just 2-4 extra cases per 1,000 women over 5 years – statistically insignificant.
- Women on estrogen-only HRT (no uterus) had lower breast cancer rates than placebo groups in studies.
Notable Quotes
“When they swapped the synthetic progestin for bioidentical progesterone, they saw no increased risk of breast cancer above a woman’s baseline.”
Bottom Line
If considering HRT, start near menopause (not decades later) using bioidentical progesterone (not synthetic progestins) and estrogen formulations – the benefits for heart/bone health far outweigh the minimal breast cancer risk.
Explore More
- Gabrielle Lyon’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
From Our Research Network
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network